Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Arkadiusz Z. Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E. Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E. Vokes, Hedy L. Kindler

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The role of maintenance therapy after first-line platinum and pemetrexed for malignant pleural mesothelioma is unknown. We performed the first-to-date randomized trial to determine if continuation of pemetrexed would improve progression-free survival over that of observation and found that primary endpoint was not different between study arms. Therefore, we cannot recommend pemetrexed continuation maintenance for treatment of malignant pleural mesothelioma.

Original languageEnglish (US)
Pages (from-to)553-561.e1
JournalClinical Lung Cancer
Volume21
Issue number6
DOIs
StatePublished - Nov 2020

Bibliographical note

Funding Information:
Dr Dudek has received honoraria from Vanquish Oncology, TTC Oncology, IGF Oncology, Squarex, and Martell Diagnostic Laboratories outside the submitted work; and has received grants to institution for his research from Merck , Eli Lilly , and Bristol-Myers Squibb . Dr Stinchcombe reports receiving grants from Genentech /Roche and AstraZeneca ; and personal fees from Regeneron, Takeda, AstraZeneca, Novartis, Genentech/Roche, and G1 Therapeutics outside the submitted work. Dr Vokes received consulting or advisory fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, and Regeneron. Dr Borghaei reports personal fees from Millennium, Merck, BMS, Lilly, Genentech, Celgene, Pfizer, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, AbbVie, Axiom, PharmaMar, Huya Bio, and Takeda outside the submitted work. Dr Kindler reports grants and personal fees from AstraZeneca , personal fees from Aldeyra Therapuetics, Astellas, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyow, Merck, Boehringer-Ingelheim, Paredox Therapeutics, Bristol-Myers Squibb, MedImmune, Aduro, Bayer, Deciphera, Glaxo Smith Kline, Lilly, Polaris, and Verastem. The remaining authors have stated that they have no conflicts of interest.

Funding Information:
Dr Dudek has received honoraria from Vanquish Oncology, TTC Oncology, IGF Oncology, Squarex, and Martell Diagnostic Laboratories outside the submitted work; and has received grants to institution for his research from Merck, Eli Lilly, and Bristol-Myers Squibb. Dr Stinchcombe reports receiving grants from Genentech/Roche and AstraZeneca; and personal fees from Regeneron, Takeda, AstraZeneca, Novartis, Genentech/Roche, and G1 Therapeutics outside the submitted work. Dr Vokes received consulting or advisory fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, and Regeneron. Dr Borghaei reports personal fees from Millennium, Merck, BMS, Lilly, Genentech, Celgene, Pfizer, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, AbbVie, Axiom, PharmaMar, Huya Bio, and Takeda outside the submitted work. Dr Kindler reports grants and personal fees from AstraZeneca, personal fees from Aldeyra Therapuetics, Astellas, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyow, Merck, Boehringer-Ingelheim, Paredox Therapeutics, Bristol-Myers Squibb, MedImmune, Aduro, Bayer, Deciphera, Glaxo Smith Kline, Lilly, Polaris, and Verastem. The remaining authors have stated that they have no conflicts of interest.The authors would like to thank James P. Zacny, PhD for assistance in manuscript preparation. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA233253, and UG1CA233327 (https://acknowledgments.alliancefound.org), and the Engdahl Family Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding Information:
The authors would like to thank James P. Zacny, PhD for assistance in manuscript preparation. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA233253, and UG1CA233327 (https://acknowledgments.alliancefound.org), and the Engdahl Family Foundation . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2020 The Author(s)

Keywords

  • Continuation pemetrexed
  • Phase II study
  • Progression-free survival
  • Unresectable mesothelioma

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Fingerprint Dive into the research topics of 'Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901'. Together they form a unique fingerprint.

Cite this